Strongbridge Biopharma (SBBP) climbs 42% after announcing results from Phase 3 study evaluating RECORLEV for treatment of endogenous Cushing’s syndrome

August 8, 2018 6:45 AM

Strongbridge Bio (NASDAQ: SBBP) climbs ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found